Literature DB >> 30481929

[The incidence and mortality of lung cancer in China, 2014].

K X Sun1, R S Zheng1, H M Zeng1, S W Zhang1, X N Zou1, X Y Gu2, C F Xia1, Z X Yang1, H Li1, W Q Chen3, J He4.   

Abstract

Objective: To estimate lung cancer incidence and mortality in China using population-based cancer registry data in 2014 collected by National Central Cancer Registry of China (NCCRC).
Methods: 449 cancer registries submitted cancer registry data in 2014. All datasets were evaluated and 339 registries' data which met the quality control criteria of NCCRC were analyzed. Numbers of new lung cancer cases and deaths were estimated using calculated incidence and mortality rates and corresponding national population stratified by areas, sexes and age groups. The standard population of Chinese census in 2000 and world Segi' s population were applied to calculate age-standardized incidence and mortality rates in China and worldwide, respectively.
Results: A total of 781, 500 new lung cancer cases were diagnosed in 2014. The crude incidence rate was 57.13 per 100 000 and the age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 36.71 per 100 000 and 36.63 per 100 000, respectively. The cumulative incidence rate (0-74 years old) was 4.50%. Lung cancer was the most common cancer in male (ASIRW: 50.04 per 100 000) and the second most common cancer in female (ASIRW: 23.63 per 100 000). The incidence rates were slightly similar in urban areas and in rural areas (ASIRW: 36.64 per 100 000 vs 36.56 per 100 000). A total of 626 400 lung cancer deaths were reported. The crude mortality rate was 45.80 per 100 000 and the age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 28.49 per 100 000 and 28.31 per 100 000, respectively. The cumulative mortality rate (0-74 years old) was 3.32%. Lung cancer was the most common cause of cancer deaths both in male (ASMRW: 40.21 per 100 000) and female (ASMRW: 16.88 per 100 000). The mortality rate was slightly higher in rural areas than in urban areas (ASMRW: 28.63 per 100 000 vs 28.04 per 100 000). Both lung cancer incidence and mortality rates increased with age, and the peak age was 80-84 years group. Conclusions: The disease burden of lung cancer is heavy in China. Efficient national health policies and prevention and control strategies against lung cancer should be promoted.

Entities:  

Keywords:  Cancer registry; China; Incidence; Lung neoplasms; Mortality

Mesh:

Year:  2018        PMID: 30481929     DOI: 10.3760/cma.j.issn.0253-3766.2018.11.002

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  13 in total

1.  Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential.

Authors:  Zhenkun Liu; Song Xu; Lu Li; Xiaorong Zhong; Chun Chen; Yaguang Fan; Wang Shen; Lingling Zu; Feng Xue; Min Wang; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2019-04-04       Impact factor: 3.500

2.  Bioinformatics analysis of microarray data to identify the candidate biomarkers of lung adenocarcinoma.

Authors:  Tingting Guo; Hongtao Ma; Yubai Zhou
Journal:  PeerJ       Date:  2019-07-10       Impact factor: 2.984

3.  Comparative evaluation of image registration methods with different interest regions in lung cancer radiotherapy.

Authors:  Xiaohui Cao; Ming Liu; Fushan Zhai; Nan Li; Feng Li; Chaoen Bao; Yinliang Liu; Gang Chen
Journal:  BMC Med Imaging       Date:  2019-12-26       Impact factor: 1.930

4.  Long Intergenic Non-Protein Coding RNA 01089 Weakens Tumor Proliferation, Migration, and Invasion by Sponging miR-3187-3p in Non-Small Cell Lung Cancer.

Authors:  Dongdong Zhang; Xingdong Cai; Songwang Cai; Wenyou Chen; Chuang Hu
Journal:  Cancer Manag Res       Date:  2020-11-25       Impact factor: 3.989

5.  SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.

Authors:  Xiaolin Ji; Yan Liu; Fang Mei; Xinyang Li; Mengxue Zhang; Buwen Yao; Rui Wu; Jiangfeng You; Fei Pei
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

6.  Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma.

Authors:  Xiaohan Ma; Huijun Ren; Ruoyu Peng; Yi Li; Liang Ming
Journal:  PeerJ       Date:  2020-05-06       Impact factor: 2.984

7.  TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC.

Authors:  Ming Lou; Zhaojia Gao; Tao Zhu; Xiaoliang Mao; Yeming Wang; Kai Yuan; Jichun Tong
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

8.  Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma.

Authors:  Yuan Zhang; Jianbo Chen; Yunan Zhao; Lihong Weng; Yiquan Xu
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

9.  Association between CYP2A13 polymorphisms and lung cancer: A protocol for systematic review and meta-analysis.

Authors:  Long Ma; Gang Jin; Yi Yang; Yao Pang; Wenhao Wang; Hongyi Zhang; Jiawei Liu; Peng Wu; Zequan Wang; Kui Wang; Ruitong Chang; Jialong Li; Zijiang Zhu
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

10.  Mannose Impairs Lung Adenocarcinoma Growth and Enhances the Sensitivity of A549 Cells to Carboplatin.

Authors:  Jun Sha; Dandan Cao; Rui Cui; Lu Xia; Xin Hua; Yuan Lu; Shuhua Han
Journal:  Cancer Manag Res       Date:  2020-11-03       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.